Mouse Anti-CAPS Recombinant Antibody (4C6) (CBMAB-C6735-LY)

Zhu, Z., Wang, J., Tan, J., Yao, Y., He, Z., Xie, X., ... & Bian, X. (2021). Calcyphosine promotes the proliferation of glioma cells and serves as a potential therapeutic target. The Journal of Pathology.

Pan, H., Xiang, H., Wang, J., Wei, Z., Zhou, Y., Liu, B., ... & Wang, B. (2019). CAPS mutations are potentially associated with unexplained recurrent pregnancy loss. The American journal of pathology, 189(1), 124-131.

Al-Hakeim, H. K., & Alhillawi, Z. H. (2018). Effect of serum fibroblast growth factor receptor 2 and CAPS proteins on calcium status in β-thalassaemia major patients who are free from overt inflammation. Growth Factors, 36(3-4), 178-185.

Wang, Q., Zhu, L., Jiang, Y., Xu, J., Wang, F., & He, Z. (2017). miR‑219‑5p suppresses the proliferation and invasion of colorectal cancer cells by targeting calcyphosin. Oncology letters, 13(3), 1319-1324.

Li, F., Zhu, D., Yang, Y., Wu, K., & Zhao, S. (2017). Overexpression of calcyphosine is associated with poor prognosis in esophageal squamous cell carcinoma. Oncology letters, 14(5), 6231-6237.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols